Clinical trialPhase 1Active not recruiting
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Phase Ib Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 17 October 2019
- Expected end
- April 2027
- Enrollment
- 7 participants
- Sites
- 2
- Primary outcomes
- Evaluate toxicity
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 May 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.